Novartis Forecast, price target & analysts
Novartis Target price 2025 - Analyst rating & recommendation
Novartis Classifications & Recommendation:
Novartis Price Target
| Target Price | CHF107.10 |
| Price | CHF96.02 |
| Potential | 11.54% |
| Number of Estimates | 25 |
| 25 Analysts have issued a price target Novartis 2026 . The average Novartis target price is CHF107.10. This is 11.54% higher than the current stock price. The highest price target is CHF124.95 30.13% , the lowest is CHF78.78 17.95% . | |
| A rating was issued by 32 analysts: 12 Analysts recommend Novartis to buy, 16 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Novartis stock has an average upside potential 2026 of 11.54% . Most analysts recommend the Novartis stock at Hold. |
Sales and Margin forecast 2025, 2026 to 2032
26 Analysts have issued a sales forecast Novartis 2025 . The average Novartis sales estimate is CHF44.4b . This is 4.13% higher than the revenue of the last 12 months(TTM). The highest sales forecast is CHF48.9b 14.65% , the lowest is CHF40.9b 4.11% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | CHF41.4b | 10.85% |
|---|---|---|
| 2025 | CHF44.4b | 7.22% |
| 2026 | CHF45.2b | 1.94% |
| 2027 | CHF46.3b | 2.43% |
| 2028 | CHF47.4b | 2.38% |
| 2029 | CHF48.7b | 2.57% |
| 2030 | CHF49.4b | 1.58% |
| 2031 | CHF47.9b | 2.99% |
| 2032 | CHF44.0b | 8.28% |
20 Analysts have issued an Novartis EBITDA forecast 2025. The average Novartis EBITDA estimate is CHF18.1b . This is 28.23% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is CHF19.8b 40.07% , the lowest is CHF13.7b 3.31% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | CHF13.2b | 26.63% |
|---|---|---|
| 2025 | CHF18.1b | 37.09% |
| 2026 | CHF18.5b | 2.15% |
| 2027 | CHF19.2b | 3.55% |
| 2028 | CHF21.0b | 9.37% |
| 2029 | CHF22.0b | 5.04% |
| 2030 | CHF21.6b | 1.91% |
| 2031 | CHF18.2b | 15.97% |
| 2032 | CHF16.0b | 12.15% |
EBITDA Margin
| 2024 | 31.96% | 14.24% |
|---|---|---|
| 2025 | 40.86% | 27.86% |
| 2026 | 40.94% | 0.20% |
| 2027 | 41.39% | 1.10% |
| 2028 | 44.22% | 6.84% |
| 2029 | 45.28% | 2.40% |
| 2030 | 43.73% | 3.42% |
| 2031 | 37.88% | 13.38% |
| 2032 | 36.28% | 4.22% |
26 Novartis Analysts have issued a net profit forecast 2025. The average Novartis net profit estimate is CHF13.6b . This is 32.46% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is CHF15.9b 54.45% , the lowest is CHF11.4b 10.64% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | CHF9.6b | 19.59% |
|---|---|---|
| 2025 | CHF13.6b | 42.64% |
| 2026 | CHF14.2b | 4.20% |
| 2027 | CHF15.3b | 7.53% |
| 2028 | CHF16.1b | 5.57% |
| 2029 | CHF16.8b | 4.14% |
| 2030 | CHF16.9b | 0.76% |
| 2031 | CHF15.0b | 11.25% |
| 2032 | CHF13.0b | 13.42% |
Net Margin
| 2024 | 23.09% | 27.46% |
|---|---|---|
| 2025 | 30.71% | 33.02% |
| 2026 | 31.40% | 2.25% |
| 2027 | 32.96% | 4.97% |
| 2028 | 33.99% | 3.13% |
| 2029 | 34.51% | 1.53% |
| 2030 | 34.23% | 0.81% |
| 2031 | 31.32% | 8.50% |
| 2032 | 29.56% | 5.62% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
26 Analysts have issued a Novartis forecast for earnings per share. The average Novartis EPS is CHF6.96 . This is 34.10% higher than earnings per share in the financial year 2024. The highest EPS forecast is CHF8.11 56.26% , the lowest is CHF5.81 11.95% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | CHF4.70 | 17.11% |
|---|---|---|
| 2025 | CHF6.96 | 48.09% |
| 2026 | CHF7.25 | 4.17% |
| 2027 | CHF7.79 | 7.45% |
| 2028 | CHF8.23 | 5.65% |
| 2029 | CHF8.57 | 4.13% |
| 2030 | CHF8.63 | 0.70% |
| 2031 | CHF7.66 | 11.24% |
| 2032 | CHF6.64 | 13.32% |
P/E ratio
| Current | 18.50 | 20.66% |
|---|---|---|
| 2025 | 13.80 | 25.41% |
| 2026 | 13.25 | 3.99% |
| 2027 | 12.32 | 7.02% |
| 2028 | 11.67 | 5.28% |
| 2029 | 11.21 | 3.94% |
| 2030 | 11.12 | 0.80% |
| 2031 | 12.53 | 12.68% |
| 2032 | 14.47 | 15.48% |
Based on analysts' sales estimates for 2025, the Novartis stock is valued at an EV/Sales of 4.51 and an P/S ratio of 4.07 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 4.69 | 15.95% |
|---|---|---|
| 2025 | 4.51 | 3.87% |
| 2026 | 4.42 | 1.91% |
| 2027 | 4.32 | 2.38% |
| 2028 | 4.22 | 2.32% |
| 2029 | 4.11 | 2.50% |
| 2030 | 4.05 | 1.55% |
| 2031 | 4.17 | 3.08% |
| 2032 | 4.55 | 9.03% |
P/S ratio
| Current | 4.24 | 18.60% |
|---|---|---|
| 2025 | 4.07 | 3.97% |
| 2026 | 4.00 | 1.90% |
| 2027 | 3.90 | 2.38% |
| 2028 | 3.81 | 2.32% |
| 2029 | 3.72 | 2.50% |
| 2030 | 3.66 | 1.55% |
| 2031 | 3.77 | 3.08% |
| 2032 | 4.11 | 9.03% |
Current Novartis Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BERENBERG |
Hold
➜
Hold
|
Unchanged | Apr 07 2025 |
| ARGUS RESEARCH CORPORATION |
Hold
➜
Hold
|
Unchanged | Apr 06 2025 |
| TD COWEN |
Hold
➜
Hold
|
Unchanged | Apr 06 2025 |
| DAY BY DAY |
Buy
➜
Buy
|
Unchanged | Mar 23 2025 |
| REDBURN ATLANTIC |
Sell
➜
Sell
|
Unchanged | Mar 21 2025 |
| GUGGENHEIM SECURITIES LLC |
Neutral
➜
Neutral
|
Unchanged | Mar 17 2025 |
| CHINA MERCHANTS SECURITIES CO., LTD |
Buy
➜
Buy
|
Unchanged | Mar 04 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
BERENBERG:
Hold
➜
Hold
|
Apr 07 2025 |
|
Unchanged
ARGUS RESEARCH CORPORATION:
Hold
➜
Hold
|
Apr 06 2025 |
|
Unchanged
TD COWEN:
Hold
➜
Hold
|
Apr 06 2025 |
|
Unchanged
DAY BY DAY:
Buy
➜
Buy
|
Mar 23 2025 |
|
Unchanged
REDBURN ATLANTIC:
Sell
➜
Sell
|
Mar 21 2025 |
|
Unchanged
GUGGENHEIM SECURITIES LLC:
Neutral
➜
Neutral
|
Mar 17 2025 |
|
Unchanged
CHINA MERCHANTS SECURITIES CO., LTD:
Buy
➜
Buy
|
Mar 04 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
